Replies to post #731535 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

From that same MHRA meeting, the MHRA pointed out that they had their most productive meeting with the FDA recently. I don’t see them primarily as competitors but rather cooperative niches.

[exwannabe]

The "platform" remark by the head of the MHRA was not about NWBO.

She was talking about a couple candidates using genetic screening to determine the precise treatment. One would likely be the MRK-Moderna RNA onco vaccine. The reason for her statement is how do you approve a "drug" that can have 2^34 possible forms?

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor.

.

Not sure what the other is, but not -L.

That NWBO calls -L a platform is nothing new. That term has been use by biotechs for 2 decades to describe their technology. Kind of like MRK using "franchise": to describe Keytruda becaming an industry buzword over the years. And that does not mean MRK sells it though McDs.